title: Hepatitis B e antigen and hepatitis B surface antigen seroclearance with the emergence of lamivudine-associated and core mutations following CD4 elevation in a patient with hepatitis B and HIV.
abstract: Obtaining a better understanding of the mechanisms associated with hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) loss in patients with hepatitis B virus (HBV) is important for treating patients with chronic hepatitis B. We herein describe the case of a patient with HBV and human immunodeficiency virus whose chronic hepatitis was stabilized due to HBe and HBs seroconversion with the emergence of lamivudine-associated and core mutations after CD4 elevation. A full-length HBV DNA analysis indicated that HBsAg had been lost after the development of the rtS143T mutation, which corresponded to the emergence of the sF134L and core mutations. The details of this case shed some light on the mechanisms associated with HBsAg and HBeAg clearance.
authors: Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Japan.
authors: Takashi
authors: T
authors: Honda
authors: Masatoshi
authors: M
authors: Ishigami
authors: Fangqiong
authors: F
authors: Luo
authors: Yoji
authors: Y
authors: Ishizu
authors: Teiji
authors: T
authors: Kuzuya
authors: Kazuhiko
authors: K
authors: Hayashi
authors: Akihiro
authors: A
authors: Itoh
authors: Yoshiki
authors: Y
authors: Hirooka
authors: Tetsuya
authors: T
authors: Ishikawa
authors: Isao
authors: I
authors: Nakano
authors: Yoshiaki
authors: Y
authors: Katano
authors: Hidemi
authors: H
authors: Goto
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004279:DNA, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D006513:Hepatitis B e Antigens / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D009154:Mutation
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D019259:Lamivudine